Avidity Biosciences (RNA) Stock Price, News & Analysis

Company Overview

Avidity Biosciences, Inc. is a biotechnology company focused on developing RNA-based medicines for genetic diseases. The company’s approach is designed to address conditions that are difficult to treat with conventional oligonucleotide therapies, including diseases affecting skeletal muscle.

Avidity’s proprietary AOC (antibody oligonucleotide conjugate) platform combines monoclonal antibodies with oligonucleotide-based medicines. The antibody component is intended to help deliver the therapeutic payload to specific tissues, while the oligonucleotide component is designed to modify or regulate disease-related RNA. The company’s research and development programs have included treatments for myotonic dystrophy type 1, facioscapulohumeral muscular dystrophy and Duchenne muscular dystrophy.

Founded in 2012 and headquartered in San Diego, California, Avidity became a publicly traded company in 2020. Its medicines are being developed through clinical and preclinical programs intended for patients in the United States and other international markets. Sarah Boyce serves as the company’s president and chief executive officer.

Key Stats

• Today's Range: $7.93 to $8.26
• 50-Day Range: $7.61 to $14.60
• 52-Week Range: $7.49 to $16.77
• Volume: 130,319 shs
• Average Volume: 359,815 shs
• Market Capitalization: $136.20 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $33.00
• Consensus Rating: Moderate Buy

Avidity Biosciences Stock Analysis - MarketRank™

Avidity Biosciences scored higher than 42% of companies evaluated by MarketBeat, and ranked 644th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Avidity Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on 1 strong buy rating, 4 buy ratings, 3 hold ratings, and 1 sell rating.

Upside Potential

Avidity Biosciences has a consensus price target of $33.00, representing about 314.6% upside from its current price of $7.96.

Amount of Analyst Coverage

Avidity Biosciences has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Avidity Biosciences are expected to decrease in the coming year, from ($4.45) to ($6.69) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Avidity Biosciences is -3.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Avidity Biosciences is -3.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

21.91% of the float of Avidity Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Avidity Biosciences has a short interest ratio ("days to cover") of 16.07, which indicates bearish sentiment.

Change versus previous month

Short interest in Avidity Biosciences has recently increased by 0.61%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Avidity Biosciences does not currently pay a dividend.

Dividend Growth

Avidity Biosciences does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 1.79

News Sentiment

Avidity Biosciences has a news sentiment score of 1.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Avidity Biosciences this week, compared to 2 articles on an average week.

Search Interest

Only 4 people have searched for RNA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

3 people have added Avidity Biosciences to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Avidity Biosciences insiders have not sold or bought any company stock.

Percentage Held by Institutions

Avidity Biosciences has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 11/11/2026
• Stifel 2026 Healthcare Conference 2026: 11/11/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:RNA
• CIK: 1599901
• Web: www.aviditybiosciences.com
• Phone: 858-401-7900
• Fax: N/A
• Employees: 190
• Year Founded: 2013

Price Target and Rating

• Average Price Target for Avidity Biosciences: $33.00
• High Price Target: $72.00
• Low Price Target: $15.00
• Potential Upside/Downside: +314.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.56
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.73
• Quick Ratio: 8.73

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 17,110,000
• Free Float: N/A
• Market Cap: $136.20 million
• Optionable: Optionable
• Beta: N/A